$2,480,000 of JOHNSON & JOHNSON SERVICES INC lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in OBBB Issues related to: - Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology - VA Program - Issues related to USMCA review and renegotiation - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act, regarding all provisions Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - obesity treatments - MFN - Foreign Reference Pricing - Issues related to stroke care - S. 1040, Drug Competition Enhancement Act, regarding all provisions - S. 1041, Affordable Prescriptions for Patients Act of 2025, regarding all provisions - S. 1097, Interagency Patent Coordination and Improvement Act of 2025, regarding all provisions - H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act, regarding all provisions - S.2658, Medication Affordability and Patent Integrity Act Issues related to: - intellectual property, including S. 1040, a bill to amend the Federal Trade Commission Act to prohibit product hopping - patent thickets - patent fees Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - H.R.2675, Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding - Issues related to the SUPPORT Act Issues related to - artificial intelligence - data privacy - cybersecurity - robotics"
You can find more data on corporate lobbying on Quiver Quantitative.
JNJ Congressional Stock Trading
Members of Congress have traded $JNJ stock 15 times in the past 6 months. Of those trades, 5 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by members of Congress over the last 6 months:
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
- REPRESENTATIVE KELLY MORRISON sold up to $15,000 on 08/19.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 08/14.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 2 purchases worth up to $30,000 on 08/04, 06/17 and 1 sale worth up to $15,000 on 06/24.
- REPRESENTATIVE THOMAS H. KEAN, JR. sold up to $50,000 on 07/31.
- REPRESENTATIVE SCOTT FRANKLIN sold up to $50,000 on 06/16.
- REPRESENTATIVE PETE SESSIONS sold up to $50,000 on 06/12.
- REPRESENTATIVE LLOYD DOGGETT purchased up to $15,000 on 06/10.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $50,000 on 05/30 and 1 sale worth up to $15,000 on 04/29.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $100,000 on 05/12.
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 05/05.
- REPRESENTATIVE BRUCE WESTERMAN sold up to $15,000 on 04/21.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
JNJ Insider Trading Activity
JNJ insiders have traded $JNJ stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by insiders over the last 6 months:
- JOAQUIN DUATO (CEO and Chairman of the Board) sold 125,824 shares for an estimated $22,548,654
- JENNIFER L TAUBERT (EVP, WWC. Innovative Medicine) sold 56,471 shares for an estimated $10,040,882
- JOHN C REED (EVP, Innovative Medicine, R&D) sold 19,137 shares for an estimated $3,129,829
- JOSEPH J WOLK (Exec VP, CFO) sold 16,820 shares for an estimated $2,975,570
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
JNJ Hedge Fund Activity
We have seen 1,735 institutional investors add shares of JNJ stock to their portfolio, and 2,027 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 4,482,323 shares (+2.2%) to their portfolio in Q2 2025, for an estimated $684,674,838
- INVESCO LTD. removed 4,457,751 shares (-24.1%) from their portfolio in Q2 2025, for an estimated $680,921,465
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 3,319,402 shares (+20.3%) to their portfolio in Q2 2025, for an estimated $507,038,655
- CAPITAL INTERNATIONAL INVESTORS removed 3,101,458 shares (-83.8%) from their portfolio in Q2 2025, for an estimated $473,747,709
- VANGUARD GROUP INC added 3,085,180 shares (+1.3%) to their portfolio in Q2 2025, for an estimated $471,261,245
- PACER ADVISORS, INC. removed 2,632,092 shares (-84.2%) from their portfolio in Q3 2025, for an estimated $488,042,498
- KINGSTONE CAPITAL PARTNERS TEXAS, LLC removed 2,476,715 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $459,232,495
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
JNJ Analyst Ratings
Wall Street analysts have issued reports on $JNJ in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 10/14/2025
- Citigroup issued a "Buy" rating on 10/07/2025
- Wells Fargo issued a "Overweight" rating on 10/03/2025
- RBC Capital issued a "Outperform" rating on 07/17/2025
To track analyst ratings and price targets for JNJ, check out Quiver Quantitative's $JNJ forecast page.
JNJ Price Targets
Multiple analysts have issued price targets for $JNJ recently. We have seen 14 analysts offer price targets for $JNJ in the last 6 months, with a median target of $202.0.
Here are some recent targets:
- Rick Wise from Stifel set a target price of $190.0 on 10/15/2025
- Terence Flynn from Morgan Stanley set a target price of $190.0 on 10/15/2025
- Joanne Wuensch from Citigroup set a target price of $215.0 on 10/15/2025
- Jayson Bedford from Raymond James set a target price of $209.0 on 10/15/2025
- Tim Anderson from B of A Securities set a target price of $204.0 on 10/15/2025
- Danielle Antalffy from UBS set a target price of $214.0 on 10/14/2025
- Asad Haider from Goldman Sachs set a target price of $212.0 on 10/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
